APA (7th ed.) Citation

PE, C. (2026). Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. European urology. https://doi.org/10.1016/j.eururo.2026.02.006

Chicago Style (17th ed.) Citation

PE, Clark. "Re: Durvalumab in Combination with BCG for BCG-naive, High Risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial." European Urology 2026. https://doi.org/10.1016/j.eururo.2026.02.006.

MLA (9th ed.) Citation

PE, Clark. "Re: Durvalumab in Combination with BCG for BCG-naive, High Risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial." European Urology, 2026, https://doi.org/10.1016/j.eururo.2026.02.006.